BTK inhibitors have been investigated in various autoimmune disorders, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), multiple sclerosis (MS), atopic dermatitis (AD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren’s disease (SD), multiple sclerosis (MS), and pemphigus vulgaris (PV). The gene discussed is BTK; the disease is autoimmune hemolytic anemia.